20 Oct 2017 07:00
Press release | October 20, 2017 |
Verseon Corporation
("Verseon" or the "Company")
Results of Special Shareholder Meeting and Appointment of Dr. Robert W. Karr to the Board of Directors
FREMONT, Calif.-Verseon Corporation (AIM:VSN), a technology-based pharmaceutical company, is pleased to announce that Dr. Robert W. Karr was elected as a Non-Executive Class II Director ("Director") of the Company, effective immediately, at the Company's Special Shareholder Meeting ("Special Meeting") held on October 19, 2017 at 14:00 PDT.
As detailed in the announcement of the Special Meeting made on September 25, 2017, Dr. Karr has previously served in a range of senior management roles in the pharmaceutical and biotech industry, including Senior Vice President of R&D Strategy at Pfizer and Chief Scientific Officer at Tioma Therapeutics. He brings to Verseon broad expertise spanning drug discovery and development, clinical trials, as well as investor relations and partnering efforts.
Commenting on Dr. Karr's appointment, Adityo Prakash, Chief Executive Officer said: "We are delighted to welcome Dr. Karr to Verseon's Board of Directors. For many years he has helped shape Verseon's drug programs as a member of our Scientific Advisory Board, and we are excited that he has now agreed to serve as a Non-Executive Director. Verseon is entering a significant period as we prepare to advance some of our drug programs into clinical trials. With his wealth of experience and unique understanding of the global pharmaceutical industry, Dr. Karr will provide valuable leadership and strategic insight."
"I am excited to join Verseon's Board of Directors," said Dr. Karr. "I have supported the Company since its early years because I recognized the potential impact of Verseon's disruptive platform on drug discovery. The recent results across the Company's pipeline, and in particular the progress toward clinical trials, show that Verseon is realizing this potential. I look forward to working with Verseon's interdisciplinary team."
Other Information
In relation to the appointment of Dr. Karr, the Company confirms that there is no further information to be disclosed under paragraph (g) of Schedule 2 of the AIM Rules for Companies save as disclosed below:
Full Name: | Robert William Karr |
Age: | 69 |
Current Directorships / Partnership: | Tansna Therapeutics, Inc. |
Previous Directorships / Partnership in the past 5 years: | Idera Pharmaceuticals, Inc. Vasculox, Inc. Antegrin Therapeutics LLC Mencuro Therapeutics, Inc. Medros, Inc. |
Shareholding in the Company | 185,264 shares |
- Ends -
For further information, please contact
Verseon Corporation | www.verseon.com |
Tina Schlafly | +1 (510) 225 9000 |
Cenkos Securities (NOMAD and Joint Broker) | |
Neil McDonald / Beth McKiernan | +44 (0) 20 7397 8900 |
Cantor Fitzgerald Europe (Joint Broker) | |
Marc Milmo / Phil Davies / Callum Butterfield | +44 (0) 20 7894 7000 |
Mirabaud Securities LLP (Joint Broker) | |
Peter Krens | +44 (0) 20 7321 2508 |
For financial and business media enquiries, please contact
Buchanan Communications Ltd (PR Advisers) | |
Henry Harrison-Topham / Jamie Hooper | +44 (0) 20 7466 5000 |
For trade and pharma media enquiries, please contact
Vane Percy & Roberts | |
Simon Vane Percy | +44 (0) 1737 821 890 |